aTyr Pharma, Inc. (ATYR) vs Seres Therapeutics, Inc. (MCRB)
A side-by-side comparison of aTyr Pharma, Inc. and Seres Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ATYR
aTyr Pharma, Inc.
$0.29HealthcareDelayed quote: Oct 6, 2026, 12:09 PM EDT
MCRB
Seres Therapeutics, Inc.
$2.85HealthcareDelayed quote: Oct 6, 2026, 12:04 PM EDT
Total return — ATYR vs MCRB
growth of $100 · dividends reinvested · last 2yATYR -83.2% (-59.1%/yr)MCRB -85.8% (-62.3%/yr)ATYR compounded faster over this window
ATYR MCRB
ATYR vs MCRB: by the numbers
- •ATYR is the larger company ($29M vs $28M market cap).
- •Both run net losses; MCRB's is the smaller (-1192.94% vs -32003.68% net margin).
- •Both shrank revenue over the past five years; ATYR's decline was smaller (-38.74% vs -42.51% CAGR).
Metrics side by side
Valuation
| Metric | ATYR | MCRB |
|---|---|---|
| P/S ratio | 151.46 | 14.66 |
| P/B ratio | 0.59 | 0.80 |
Profitability
| Metric | ATYR | MCRB |
|---|---|---|
| Gross margin | -717.37% | -423.83% |
| Operating margin | -40856.32% | -11910.14% |
| Net margin | -32003.68% | -1192.94% |
| ROE | -124.64% | -65.05% |
| ROIC | -109.29% | -103.04% |
Growth (annualized)
| Metric | ATYR | MCRB |
|---|---|---|
| Revenue CAGR (5Y) | -38.74% | -42.51% |
| Total return CAGR (5Y) | N/A | -53.37% |
Frequently asked
- Which has grown faster, ATYR or MCRB?
- Neither grew: over the past five years both shrank revenue, with ATYR's decline the smaller — ATYR at a -38.74% CAGR versus MCRB at -42.51%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.